Tirofiban injection is used to prevent blood clots from forming in the arteries of the heart after certain types of chest pain and heart attacks. It may also be used in patients who are undergoing specific heart and blood vessel procedures. Tirofiban is an antiplatelet medicine belonging to a class of drugs known as glycoprotein IIb/IIIa inhibitors, which prevent platelets in the blood from clumping together, thereby reducing the formation of harmful blood clots in the arteries. Tirofiban is commonly administered via intravenous infusion in a hospital setting, particularly for patients undergoing procedures like percutaneous coronary intervention (PCI). It is marketed under the brand name Aggrastat.
During the production and storage of Tirofiban, impurities may form, which must be controlled to ensure the drug’s safety and efficacy. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), set guidelines on permissible impurity levels in Tirofiban formulations.
Tirofiban is used to reduce the risk of acute coronary syndrome (ACS), including heart attack and unstable angina. It helps prevent blood clot formation in patients at risk for these conditions, particularly those undergoing percutaneous coronary intervention (PCI).
Tirofiban is an antiplatelet medication. It works by inhibiting glycoprotein IIb/IIIa receptors on platelets, reducing their ability to clump together and form clots, which distinguishes it from anticoagulants that affect the blood clotting cascade.
Aggrastat is the brand name for Tirofiban. It is an antiplatelet drug and a glycoprotein IIb/IIIa inhibitor, used to prevent platelet aggregation in patients with acute coronary syndrome.
Currently, there is no specific antidote for Tirofiban. If significant bleeding occurs, the infusion can be stopped, and supportive measures such as platelet transfusions may be administered to restore normal clotting.
